Core Viewpoint - The company, Shanxi Dayu Biological Engineering Co., Ltd., reported a significant increase in revenue for the year 2025, but continued to face net losses, marking the third consecutive year of losses since 2023 [1][2]. Group 1: Financial Performance - The company achieved an operating income of 168 million yuan, representing a year-on-year growth of 36.78% [1]. - The net profit attributable to shareholders was a loss of 28.79 million yuan, which is a 20.23% increase in the loss compared to the previous year [1]. - Total assets are expected to reach 434 million yuan by the end of 2025, reflecting a growth of 10.39% from the beginning of the year [2]. - The equity attributable to shareholders decreased by 9.81% to 265 million yuan, with the net asset per share dropping to 2.39 yuan [2]. - The weighted average return on equity fell to -10.32%, further declining compared to the previous year [2]. Group 2: Business Segments - The revenue growth in 2025 was primarily driven by the newly expanded pig farming business, which contributed 42.19 million yuan to the total revenue [1]. - The pig farming segment's profitability was adversely affected by a significant drop in market prices in the fourth quarter of 2025, leading to increased net losses by 4.84 million yuan compared to the previous year [1]. - Traditional business segments, including feed additives, feed, and veterinary drugs, faced challenges due to industry capacity adjustments and the impact of African swine fever, resulting in a decline in gross profit [1].
大禹生物，连亏三年